Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 65Neoplasm Metastasis 56Leukemia, Myeloid, Acute 55Multiple Myeloma 44Prostatic Neoplasms 43Melanoma 43Lung Neoplasms 39Colorectal Neoplasms 36Lymphoma 33Pancreatic Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Carcinoma, Non-Small-Cell Lung 29Myelodysplastic Syndromes 26Squamous Cell Carcinoma of Head and Neck 25Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 22Neoplasms 22Ovarian Neoplasms 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Sarcoma 17Lymphoma, Mantle-Cell 17Glioma 17Uterine Cervical Neoplasms 16Rectal Neoplasms 16Leukemia, Myelomonocytic, Chronic 15Fallopian Tube Neoplasms 15Stomach Neoplasms 14

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Endometrial Stromal × Biopsy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡